Management of Dyslipidemia and Atherosclerotic Cardiovascular Risk in Prediabetes.

[1]  K. Gadde,et al.  Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study , 2022, Circulation.

[2]  E. Huang,et al.  3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[3]  B. Davis,et al.  Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis , 2021, The Lancet.

[4]  K. Gadde,et al.  Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study , 2021, Diabetes Care.

[5]  F. Knop,et al.  Prediabetes Defined by First Measured HbA1c Predicts Higher Cardiovascular Risk Compared With HbA1c in the Diabetes Range: A Cohort Study of Nationwide Registries , 2021, Diabetes Care.

[6]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[7]  B. Nordestgaard,et al.  A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. , 2021, European heart journal.

[8]  M. Cabana,et al.  Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. , 2021, JAMA.

[9]  K. Narayan,et al.  Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis , 2021, BMJ Open Diabetes Research & Care.

[10]  Yuli Huang,et al.  Prediabetes and the risk of heart failure: A meta‐analysis , 2021, Diabetes, obesity & metabolism.

[11]  T. Wadden,et al.  Once-Weekly Semaglutide in Adults with Overweight or Obesity. , 2021, The New England journal of medicine.

[12]  J. Pankow,et al.  Risk of Progression to Diabetes Among Older Adults With Prediabetes. , 2021, JAMA internal medicine.

[13]  P. Ponikowski,et al.  Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF , 2020, Diabetes Care.

[14]  Zhen Wang,et al.  Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-analysis. , 2020, The Journal of clinical endocrinology and metabolism.

[15]  Jeffrey B. Boord,et al.  Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. , 2020, The Journal of clinical endocrinology and metabolism.

[16]  W. Masson,et al.  Effect of bempedoic acid onnew onset or worseningdiabetes: a meta-analysis. , 2020, Diabetes research and clinical practice.

[17]  Jason H. Y. Wu,et al.  Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis , 2020, BMJ.

[18]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[19]  A. Keech,et al.  Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. , 2020, The lancet. Diabetes & endocrinology.

[20]  A. Stewart,et al.  Coagulatory Defects in Type-1 and Type-2 Diabetes , 2019, International journal of molecular sciences.

[21]  F. Rutters,et al.  Risk and management of pre-diabetes , 2019, European journal of preventive cardiology.

[22]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[23]  Deepak L. Bhatt,et al.  Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[24]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[25]  Antonio Ceriello,et al.  Glycaemic variability in diabetes: clinical and therapeutic implications. , 2019, The lancet. Diabetes & endocrinology.

[26]  L. Goldstein,et al.  Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[27]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[28]  Yuan-Lin Guo,et al.  Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes , 2018, Hypertension.

[29]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.

[30]  S. Saydah,et al.  Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014. , 2018, The lancet. Diabetes & endocrinology.

[31]  M. Buysschaert,et al.  The 1-h post-load plasma glucose as a novel biomarker for diagnosing dysglycemia , 2018, Acta Diabetologica.

[32]  Lawrence A Leiter,et al.  Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[33]  Deepak L. Bhatt,et al.  Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study , 2017, Diabetes Care.

[34]  James R. Powell,et al.  Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial , 2017, Diabetes Care.

[35]  T. Vilsbøll,et al.  Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. , 2017, Journal of diabetes and its complications.

[36]  Eliot A Brinton,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[37]  Iciar Martín-Timón,et al.  Management of Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients , 2016, European Medical Journal.

[38]  A. Chetrit,et al.  One‐hour post‐load plasma glucose level during the OGTT predicts mortality: observations from the Israel Study of Glucose Intolerance, Obesity and Hypertension , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[39]  E. France,et al.  Prevalence of impaired glucose regulation in Europe: a meta-analysis. , 2016, European journal of public health.

[40]  H F Jelinek,et al.  Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes--Biomarkers as a possible tool for early disease detection for rural screening. , 2015, Clinical biochemistry.

[41]  D. Alexander,et al.  Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. , 2015, Journal of clinical lipidology.

[42]  B. Vergès.  Pathophysiology of diabetic dyslipidaemia: where are we? , 2015, Diabetologia.

[43]  Martin Buysschaert,et al.  Prediabetes and associated disorders , 2015, Endocrine.

[44]  D. Waters,et al.  Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. , 2015, Journal of the American College of Cardiology.

[45]  A. Adler,et al.  Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis , 2014, Diabetologia.

[46]  Anne M. Tomolo,et al.  Aging is associated with increased HbA1c levels, independently of glucose levels and insulin resistance, and also with decreased HbA1c diagnostic specificity , 2014, Diabetic medicine : a journal of the British Diabetic Association.

[47]  M. Rewers,et al.  Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. , 2013, The Journal of clinical endocrinology and metabolism.

[48]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[49]  G. Davı̀,et al.  Diabetes mellitus and thrombosis. , 2012, Thrombosis research.

[50]  S. Keinänen-Kiukaanniemi,et al.  Limited Overlap Between Intermediate Hyperglycemia as Defined by A1C 5.7–6.4%, Impaired Fasting Glucose, and Impaired Glucose Tolerance , 2011, Diabetes Care.

[51]  J. Crandall,et al.  Mechanisms of vascular complications in prediabetes. , 2011, The Medical clinics of North America.

[52]  R. DeFronzo.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 , 2010, Diabetologia.

[53]  Hong Li,et al.  Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation , 2010, Endocrine.

[54]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[55]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[56]  S. Haffner,et al.  The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. , 2007, Annals of epidemiology.

[57]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[58]  J. Meigs,et al.  Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. , 2004, Diabetes.

[59]  A. Keech,et al.  Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. , 2003, Diabetes care.

[60]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[61]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.